BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (NASDAQ: BIOS) is a blank-check company formed to pursue a business combination in the healthcare and life sciences sector, with a particular focus on biopharmaceutical and biotechnology targets. The company completed its initial public offering in 2021. In August 2023, BioPlus filed an S-4/A amendment with the SEC — accession number 0001193125-23-200618 — indicating that a definitive merger agreement with a target company had been announced and that the registration statement for the proposed transaction was moving through the SEC review process. As of that filing, the SPAC remained in the announced-deal phase pending shareholder and regulatory approvals. For complete data on BioPlus Acquisition Corp., including sponsor details, deal terms, and timeline milestones, sign up for full access at SpacDesk.